About cocrystal pharma inc - COCP
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create first- and best-in-class antiviral drugs. The company was founded in 2008 and is headquartered in Bothell, WA.
COCP At a Glance
Cocrystal Pharma, Inc.
19805 North Creek Parkway
Bothell, Washington 98011
| Phone | 1-305-425-1780 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -17,504,000.00 | |
| Sector | Health Technology | Employees | 11 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
COCP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.158 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.70 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.145 |
COCP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,591,272.727 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
COCP Liquidity
| Current Ratio | 4.769 |
| Quick Ratio | 4.769 |
| Cash Ratio | 4.092 |
COCP Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -78.291 |
| Return on Equity | -97.496 |
| Return on Total Capital | -154.506 |
| Return on Invested Capital | -89.707 |
COCP Capital Structure
| Total Debt to Total Equity | 18.965 |
| Total Debt to Total Capital | 15.941 |
| Total Debt to Total Assets | 13.422 |
| Long-Term Debt to Equity | 15.804 |
| Long-Term Debt to Total Capital | 13.284 |